nivolumab plus relatlimab

BIOLOGICAL2 trials

Sponsors

Salzburger Landeskliniken, Immatics US, Inc.

Conditions

Melanoma, Cutaneous MalignantSquamous Cell Carcinoma of the Skin

Phase 2

Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin

RecruitingNCT04204837

Salzburger LandesklinikenSquamous Cell Carcinoma of the Skin

Start: 2017-03-06End: 2027-12-31Target: 61Updated: 2024-04-18

Phase 3

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

RecruitingNCT06743126

Immatics US, Inc.Melanoma, Cutaneous Malignant

Start: 2025-01-14End: 2031-10-01Target: 360Updated: 2026-03-19

Related Papers

Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma.

Journal of Clinical Oncology2025-05-28

SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR-T) vs investigator’s choice in patients with previously treated advanced cutaneous melanoma.

Journal of Clinical Oncology2025-05-28

Efficacy and safety of nivolumab for locally advanced or metastatic cutaneous cell carcinoma (NIVOSQUACS trial).

Journal of Clinical Oncology2022-06-012 citations